"the great majority of [SARS-CoV2] clinical trials are focused on a small number of candidate drugs including, hydroxychloroquine, ritonavir, azithromycin, tocilizumab, lopinavir chloroquine and ivermectin (12), while potentially and more promising ones are less considered. For example, host-directed therapies such as those based on inhibitors of the human serine protease TMPRSS2 (bromhexine, camostat, and nafamostat) are considerably less explored. " https://www.frontiersin.org/articles/10.3389/fpubh.2020.00497/full